{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:36:44Z","timestamp":1790638604604,"version":"4.1.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cerebellum"],"DOI":"10.1007\/s12311-026-01994-4","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T01:11:20Z","timestamp":1776042680000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cell-Based Therapies for Spinocerebellar Degenerations: A Systematic Review of Human Clinical Evidence"],"prefix":"10.1007","volume":"25","author":[{"given":"Hamid","family":"Khalesi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehran Beiraghi","family":"Toosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arshia","family":"Khalesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Khalesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Ziaee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8469-3523","authenticated-orcid":false,"given":"Javad","family":"Akhondian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"issue":"11","key":"1994_CR1","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/S1474-4422(15)00202-1","volume":"14","author":"H Jacobi","year":"2015","unstructured":"Jacobi H, du Montcel ST, Bauer P, Giunti P, Cook A, Labrum R, et al. Long-term disease progression in spinocerebellar ataxia types 1, 2, 3, and 6: a longitudinal cohort study. Lancet Neurol. 2015;14(11):1101\u20138. https:\/\/doi.org\/10.1016\/S1474-4422(15)00202-1. Epub 20150913.","journal-title":"Lancet Neurol"},{"issue":"2","key":"1994_CR2","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1097\/NEN.0b013e31827e5762","volume":"72","author":"AH Koeppen","year":"2013","unstructured":"Koeppen AH, Mazurkiewicz JE. Friedreich ataxia: neuropathology revised. J Neuropathol Exp Neurol. 2013;72(2):78\u201390. https:\/\/doi.org\/10.1097\/NEN.0b013e31827e5762. PubMed PMID: 23334592; PubMed Central PMCID: PMC3817014.","journal-title":"J Neuropathol Exp Neurol"},{"key":"1994_CR3","doi-asserted-by":"publisher","unstructured":"Ball LG, Xiao W. Molecular basis of ataxia telangiectasia and related diseases. Acta Pharmacol Sin. 2005;26(8):897\u2013907. https:\/\/doi.org\/10.1111\/j.1745-7254.2005.00165.x. PubMed PMID: 16038621.","DOI":"10.1111\/j.1745-7254.2005.00165.x"},{"issue":"1","key":"1994_CR4","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s40478-019-0730-6","volume":"7","author":"G Monzio Compagnoni","year":"2019","unstructured":"Monzio Compagnoni G, Di Fonzo A. Understanding the pathogenesis of multiple system atrophy: state of the art and future perspectives. Acta Neuropathol Commun. 2019;7(1):113. https:\/\/doi.org\/10.1186\/s40478-019-0730-6. Epub 20190712.","journal-title":"Acta Neuropathol Commun"},{"issue":"5","key":"1994_CR5","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S1474-4422(21)00027-2","volume":"20","author":"K Reetz","year":"2021","unstructured":"Reetz K, Dogan I, Hilgers RD, Giunti P, Parkinson MH, Mariotti C, et al. Progression characteristics of the European Friedreich\u2019s Ataxia Consortium for Translational Studies (EFACTS): a 4-year cohort study. Lancet Neurol. 2021;20(5):362\u201372. https:\/\/doi.org\/10.1016\/S1474-4422(21)00027-2. Epub 20210323.","journal-title":"Lancet Neurol"},{"issue":"2","key":"1994_CR6","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s10286-021-00782-w","volume":"31","author":"JA Palma","year":"2021","unstructured":"Palma JA, Vernetti PM, Perez MA, Krismer F, Seppi K, Fanciulli A, et al. Limitations of the Unified Multiple System Atrophy Rating Scale as outcome measure for clinical trials and a roadmap for improvement. Clin Auton Res. 2021;31(2):157\u201364. https:\/\/doi.org\/10.1007\/s10286-021-00782-w. Epub 20210207.","journal-title":"Clin Auton Res"},{"issue":"2","key":"1994_CR7","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1080\/14737175.2022.2029703","volume":"22","author":"SD Ghanekar","year":"2022","unstructured":"Ghanekar SD, Kuo SH, Staffetti JS, Zesiewicz TA. Current and emerging treatment modalities for spinocerebellar ataxias. Expert Rev Neurother. 2022;22(2):101\u201314. Epub 20220210. doi: 10.1080\/14737175.2022.2029703. PubMed PMID: 35081319; PubMed Central PMCID: PMC9048095.","journal-title":"Expert Rev Neurother"},{"issue":"2","key":"1994_CR8","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/ana.25934","volume":"89","author":"DR Lynch","year":"2021","unstructured":"Lynch DR, Chin MP, Delatycki MB, Subramony SH, Corti M, Hoyle JC, et al. Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study). Ann Neurol. 2021;89(2):212\u201325. https:\/\/doi.org\/10.1002\/ana.25934. Epub 20201105.","journal-title":"Ann Neurol"},{"key":"1994_CR9","doi-asserted-by":"publisher","first-page":"1491142","DOI":"10.3389\/fneur.2024.1491142","volume":"15","author":"A Matsugi","year":"2024","unstructured":"Matsugi A, Bando K, Kondo Y, Kikuchi Y, Miyata K, Hiramatsu Y, et al. Effects of physiotherapy on degenerative cerebellar ataxia: a systematic review and meta-analysis. Front Neurol. 2024;15:1491142. https:\/\/doi.org\/10.3389\/fneur.2024.1491142. Epub 20250110.","journal-title":"Front Neurol"},{"issue":"11","key":"1994_CR10","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.3390\/biomedicines12112507","volume":"12","author":"GB Lee","year":"2024","unstructured":"Lee GB, Park SM, Jung UJ, Kim SR. The Potential of Mesenchymal Stem Cells in Treating Spinocerebellar Ataxia: Advances and Future Directions. Biomedicines. 2024;12(11):2507. https:\/\/doi.org\/10.3390\/biomedicines12112507. Epub 20241101.","journal-title":"Biomedicines"},{"issue":"8","key":"1994_CR11","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1093\/jnen\/nlaf021","volume":"84","author":"EHB Issa","year":"2025","unstructured":"Issa EHB, Alghazo EM, Gharaibeh R, Momani NB, Taha DZ, Jaradat RJ, et al. Therapeutic potential and challenges of mesenchymal stem cells in neurological disorders: A concise analysis. J Neuropathol Exp Neurol. 2025;84(8):668\u201379. https:\/\/doi.org\/10.1093\/jnen\/nlaf021. PubMed PMID: 40152120; PubMed Central PMCID: PMC12277701.","journal-title":"J Neuropathol Exp Neurol"},{"key":"1994_CR12","doi-asserted-by":"publisher","first-page":"1422442","DOI":"10.3389\/fnins.2024.1422442","volume":"18","author":"ZT Cui","year":"2024","unstructured":"Cui ZT, Mao ZT, Yang R, Li JJ, Jia SS, Zhao JL, et al. Spinocerebellar ataxias: from pathogenesis to recent therapeutic advances. Front Neurosci. 2024;18:1422442. https:\/\/doi.org\/10.3389\/fnins.2024.1422442. Epub 20240604.","journal-title":"Front Neurosci"},{"issue":"1","key":"1994_CR13","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1038\/s41598-024-53542-x","volume":"14","author":"LS Mendonca","year":"2024","unstructured":"Mendonca LS, Henriques D, Fernandes V, Moreira R, Bras J, Duarte S, et al. Graft-derived neurons and bystander effects are maintained for six months after human iPSC-derived NESC transplantation in mice\u2019s cerebella. Sci Rep. 2024;14(1):3236. https:\/\/doi.org\/10.1038\/s41598-024-53542-x. Epub 20240208.","journal-title":"Sci Rep"},{"issue":"10","key":"1994_CR14","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1177\/0963689717732578","volume":"26","author":"J Hsieh","year":"2017","unstructured":"Hsieh J, Liu JW, Harn HJ, Hsueh KW, Rajamani K, Deng YC, et al. Human Olfactory Ensheathing Cell Transplantation Improves Motor Function in a Mouse Model of Type 3 Spinocerebellar Ataxia. Cell Transpl. 2017;26(10):1611\u201321. PubMed PMID: 29251109; PubMed Central PMCID: PMC5753984.","journal-title":"Cell Transpl"},{"key":"1994_CR15","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.3389\/fimmu.2018.02495","volume":"9","author":"S Bakhtiar","year":"2018","unstructured":"Bakhtiar S, Woelke S, Huenecke S, Kieslich M, Taylor AM, Schubert R, et al. Pre-emptive Allogeneic Hematopoietic Stem Cell Transplantation in Ataxia Telangiectasia. Front Immunol. 2018;9:2495. https:\/\/doi.org\/10.3389\/fimmu.2018.02495. Epub 20181029.","journal-title":"Front Immunol"},{"issue":"5","key":"1994_CR16","doi-asserted-by":"publisher","first-page":"e83304","DOI":"10.7759\/cureus.83304","volume":"17","author":"SAM Alqarni","year":"2025","unstructured":"Alqarni SAM, Al Murayeh LM, Mushari BY, Alotaibi NH. The Use of Bone Marrow Transplantation (BMT) or Hematopoietic Stem Cell Transplantation (HSCT) in Pediatric Patients Diagnosed With Ataxia-Telangiectasia: A Systematic Review. Cureus. 2025;17(5):e83304. https:\/\/doi.org\/10.7759\/cureus.83304. Epub 20250501.","journal-title":"Cureus"},{"key":"1994_CR17","doi-asserted-by":"publisher","unstructured":"Cell-Based Therapies for Spinocerebellar Degenerations. A Systematic Review of Human Clinical Evidence [MeSH Descriptor]. OSF. 2025 [cited 2025 Oct 19]. Available from: https:\/\/doi.org\/10.17605\/OSF.IO\/DQJVN","DOI":"10.17605\/OSF.IO\/DQJVN"},{"key":"1994_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372. https:\/\/doi.org\/10.1136\/bmj.n71. Epub 20210329. :n71."},{"key":"1994_CR19","unstructured":"McKenzie JE, Brennan SE, Ryan RE, Thomson HJ, Johnston RV, Thomas J. Chapter 3: Defining the criteria for including studies and how they will be grouped for the synthesis [last updated August 2023]. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.5. Cochrane; 2024. p. 34. https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current\/chapter-03"},{"key":"1994_CR20","unstructured":"Olivopontocerebellar Atrophies [MeSH Descriptor]. National Library of Medicine. 2026. Available from: https:\/\/meshb.nlm.nih.gov\/record\/ui?ui=D009849"},{"key":"1994_CR21","unstructured":"Spinocerebellar Degenerations [MeSH Descriptor]. National Library of Medicine. 2026. Available from: https:\/\/meshb.nlm.nih.gov\/record\/ui?ui=D013132"},{"key":"1994_CR22","unstructured":"Multiple System Atrophy [MeSH Descriptor]. National Library of Medicine. 2026. Available from: https:\/\/meshb.nlm.nih.gov\/record\/ui?ui=D019578"},{"issue":"5","key":"1994_CR23","doi-asserted-by":"publisher","first-page":"e200433","DOI":"10.1212\/NXI.0000000000200433","volume":"12","author":"V Guerra","year":"2025","unstructured":"Guerra V, Cabrera-Maqueda JM, Ruiz-Garcia R, Luchoro JF, Fonseca E, Guasp M, et al. Autologous Hematopoietic Stem Cell Transplantation for Paraneoplastic Cerebellar Degeneration. Neurol Neuroimmunol Neuroinflamm. 2025;12(5):e200433. Epub 20250716. doi: 10.1212\/NXI.0000000000200433. PubMed PMID: 40669039; PubMed Central PMCID: PMC12270494.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"1994_CR24","doi-asserted-by":"publisher","unstructured":"Muraro PA, Mariottini A, Greco R, Burman J, Iacobaeus E, Inglese M et al. Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder - recommendations from ECTRIMS and the EBMT. Nat Rev Neurol. 2025;21(3):140\u201358. Epub 20250115. https:\/\/doi.org\/10.1038\/s41582-024-01050-x. PubMed PMID: 39814869.","DOI":"10.1038\/s41582-024-01050-x"},{"issue":"1","key":"1994_CR25","doi-asserted-by":"publisher","first-page":"10","DOI":"10.14802\/jmd.20040","volume":"14","author":"H Mitoma","year":"2021","unstructured":"Mitoma H, Manto M, Hadjivassiliou M. Immune-Mediated Cerebellar Ataxias: Clinical Diagnosis and Treatment Based on Immunological and Physiological Mechanisms. J Mov Disord. 2021;14(1):10\u201328. Epub 20210112. doi: 10.14802\/jmd.20040. PubMed PMID: 33423437; PubMed Central PMCID: PMC7840241.","journal-title":"J Mov Disord"},{"issue":"7","key":"1994_CR26","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S1474-4422(21)00464-6","volume":"21","author":"CM Zipser","year":"2022","unstructured":"Zipser CM, Cragg JJ, Guest JD, Fehlings MG, Jutzeler CR, Anderson AJ, et al. Cell-based and stem-cell-based treatments for spinal cord injury: evidence from clinical trials. Lancet Neurol. 2022;21(7):659\u201370. https:\/\/doi.org\/10.1016\/S1474-4422(21)00464-6. Epub 20220512.","journal-title":"Lancet Neurol"},{"issue":"1","key":"1994_CR27","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/s12916-022-02482-2","volume":"20","author":"Z Shang","year":"2022","unstructured":"Shang Z, Wang M, Zhang B, Wang X, Wanyan P. Clinical translation of stem cell therapy for spinal cord injury still premature: results from a single-arm meta-analysis based on 62 clinical trials. BMC Med. 2022;20(1):284. https:\/\/doi.org\/10.1186\/s12916-022-02482-2. Epub 20220905.","journal-title":"BMC Med"},{"issue":"7","key":"1994_CR28","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1093\/brain\/awad047","volume":"146","author":"BF Ribeiro","year":"2023","unstructured":"Ribeiro BF, da Cruz BC, de Sousa BM, Correia PD, David N, Rocha C, et al. Cell therapies for spinal cord injury: a review of the clinical trials and cell-type therapeutic potential. Brain. 2023;146(7):2672\u201393. https:\/\/doi.org\/10.1093\/brain\/awad047. PubMed PMID: 36848323.","journal-title":"Brain"},{"key":"1994_CR29","unstructured":"Chen L, Hongyun HY, Wang HM, Wang FB, Xi HT. Olfactory ensheathing cells transplantation for improving the neurological function of olivopontocerebellar atrophy in human: One case report. Journal. 2006;10:24\u20135. Available from: https:\/\/www.scopus.com\/inward\/record.uri?eid=2-s2.0-33747375839&partnerID=40&md5=5ff96a1797f751210edb3f28b641f8a3"},{"key":"1994_CR30","unstructured":"Xi H, Huang H, Chen L, Zhang F, Liu Y, Zhang J. Embryonic olfactory ensheathing cell transplantation for treating Friedreich ataxia: An analysis of outcome and safety. Journal. 2008;12:2359\u201363. Available from: http:\/\/www.zglckf.com\/zglckf\/ejournal\/upfiles\/08-12\/12k-2359(ps).pdf"},{"key":"1994_CR31","unstructured":"Miao X, Wu X, Shi W. Umbilical cord mesenchymal stem cells in neurological disorders: A clinical study. Journal. 2015;52:140\u20136. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26118125. PubMed PMID: 26118125."},{"key":"1994_CR32","unstructured":"Qing H, Ruifang L, Mengying C, Chang G, Xia Z, Lintong G. Safety and Efficacy Evaluation on the Treatment of Olivopontocerebellar Atrophy with Umbilical Cord Mesenchymal Stem Cells. Journal. 2012;33:84\u20138. Available from: https:\/\/dianda.cqvip.com\/Qikan\/Article\/Detail?id=31368790. PubMed PMID: BCI202000049985."},{"key":"1994_CR33","unstructured":"Tian ZM, Chen T, Zhong N, Li ZC, Yin F, Liu S. Clinical study of transplantation of neural stem cells in therapy of inherited cerebellar atrophy. Journal. 2009;41:456\u20138. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19727238. PubMed PMID: 19727238."},{"key":"1994_CR34","doi-asserted-by":"crossref","unstructured":"Perlman S, Lai H, ALLOGENEIC, ADIPOSE-DERIVED MESENCHYMAL STEM, CELLS (ADMSCs). TO TREAT SPINOCEREBELLAR ATAXIA (SCA) IN A US PATIENT WITH SCA TYPE 3. 2025. p. e6.","DOI":"10.1016\/j.jcyt.2025.04.012"},{"issue":"1","key":"1994_CR35","doi-asserted-by":"publisher","first-page":"14","DOI":"10.01029\/02010jb008010","volume":"23","author":"H Huang","year":"2009","unstructured":"Huang H, Chen L, Xi H, Wang Q, Zhang J, Liu Y, et al. [Olfactory ensheathing cells transplantation for central nervous system diseases in 1,255 patients]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2009;23(1):14\u201320. https:\/\/doi.org\/10.01029\/02010jb008010. PubMed PMID: 19192871.","journal-title":"Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi"},{"issue":"9","key":"1994_CR36","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1038\/bmt.2016.93","volume":"51","author":"R Beier","year":"2016","unstructured":"Beier R, Sykora KW, Woessmann W, Maecker-Kolhoff B, Sauer M, Kreipe HH, et al. Allogeneic-matched sibling stem cell transplantation in a 13-year-old boy with ataxia telangiectasia and EBV-positive non-Hodgkin lymphoma. Bone Marrow Transpl. 2016;51(9):1271\u20134. https:\/\/doi.org\/10.1038\/bmt.2016.93. Epub 20160509.","journal-title":"Bone Marrow Transpl"},{"key":"1994_CR37","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/1479-5876-9-65","volume":"9","author":"WZ Yang","year":"2011","unstructured":"Yang WZ, Zhang Y, Wu F, Zhang M, Cho SC, Li CZ, et al. Human umbilical cord blood-derived mononuclear cell transplantation: case series of 30 subjects with hereditary ataxia. J Transl Med. 2011;9:65. https:\/\/doi.org\/10.1186\/1479-5876-9-65. Epub 20110516.","journal-title":"J Transl Med"},{"issue":"1","key":"1994_CR38","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2174\/156720213804805936","volume":"10","author":"JL Jin","year":"2013","unstructured":"Jin JL, Liu Z, Lu ZJ, Guan DN, Wang C, Chen ZB, et al. Safety and efficacy of umbilical cord mesenchymal stem cell therapy in hereditary spinocerebellar ataxia. Curr Neurovasc Res. 2013;10(1):11\u201320. PubMed PMID: 23151076; PubMed Central PMCID: 23151076.","journal-title":"Curr Neurovasc Res"},{"issue":"8","key":"1994_CR39","doi-asserted-by":"publisher","first-page":"913","DOI":"10.3109\/14653249.2011.579958","volume":"13","author":"D Han","year":"2011","unstructured":"Han D, Jing L, Mei X, Ling Z, Hongmin Y, Zhidong W, et al. Clinical analysis of the treatment of spinocerebellar ataxia and multiple system atrophy-cerebellar type with umbilical cord mesenchymal stromal cells. Cytotherapy. 2011;13(8):913\u20137. https:\/\/doi.org\/10.3109\/14653249.2011.579958. Epub 20110505.","journal-title":"Cytotherapy"},{"key":"1994_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02000","author":"S Woelke","year":"2018","unstructured":"Woelke S, Valesky E, Bakhtiar S, Pommerening H, Pfeffermann LM, Schubert R, et al. Treatment of Granulomas in Patients With Ataxia Telangiectasia. Front Immunol. 2018;9. https:\/\/doi.org\/10.3389\/fimmu.2018.02000. Epub 20180918. :2000."},{"issue":"3","key":"1994_CR41","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3727\/096368916X694373","volume":"26","author":"YA Tsai","year":"2017","unstructured":"Tsai YA, Liu RS, Lirng JF, Yang BH, Chang CH, Wang YC, et al. Treatment of Spinocerebellar Ataxia With Mesenchymal Stem Cells: A Phase I\/IIa Clinical Study. Cell Transpl. 2017;26(3):503\u201312. https:\/\/doi.org\/10.3727\/096368916X694373. Epub 20170214.","journal-title":"Cell Transpl"},{"issue":"27","key":"1994_CR42","doi-asserted-by":"publisher","first-page":"5019","DOI":"10.3969\/j.issn.2095-4344.2013.27.012","volume":"17","author":"JQ Hu","year":"2013","unstructured":"Hu JQ, Ouyang WX, Li HY, Wang JF, Lu C, Zhang LN, et al. Mesenchymal stem cells for the treatment of spinocerebellar ataxia. Chin J Tissue Eng Res. 2013;17(27):5019\u201325. https:\/\/doi.org\/10.3969\/j.issn.2095-4344.2013.27.012.","journal-title":"Chin J Tissue Eng Res"},{"issue":"41","key":"1994_CR43","doi-asserted-by":"publisher","first-page":"6666","DOI":"10.3969\/j.issn.2095-4344.2014.41.019","volume":"18","author":"J Liu","year":"2014","unstructured":"Liu J, Han DM, Ding L, Xue M, Yan HM, Wang ZD, et al. Intrathecal injection of umbilical cord mesenchymal stem cells for spinocerebellar ataxia. Chin J Tissue Eng Res. 2014;18(41):6666\u201370. https:\/\/doi.org\/10.3969\/j.issn.2095-4344.2014.41.019.","journal-title":"Chin J Tissue Eng Res"},{"issue":"58","key":"1994_CR44","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.15171\/ijb.2017.s1-334","volume":"Special","author":"B Shalbafan","year":"2017","unstructured":"Shalbafan B, Mohyeddin M. The Second National Festival & International Congress on Stem Cell & Regenerative Medicine\u2009\u2013\u200913\u201315 July, 2017. Iran J Biotechnol. 2017;Special(58):s1\u2013334. https:\/\/doi.org\/10.15171\/ijb.2017.s1-334.","journal-title":"Iran J Biotechnol"},{"key":"1994_CR45","doi-asserted-by":"publisher","first-page":"891514","DOI":"10.3389\/fneur.2022.891514","volume":"13","author":"CE Kvistad","year":"2022","unstructured":"Kvistad CE, Krakenes T, Gjerde C, Mustafa K, Rekand T, Bo L. Safety and Clinical Efficacy of Mesenchymal Stem Cell Treatment in Traumatic Spinal Cord Injury, Multiple Sclerosis and Ischemic Stroke - A Systematic Review and Meta-Analysis. Front Neurol. 2022;13:891514. PubMed PMID: 35711260; PubMed Central PMCID: PMC9196044.","journal-title":"Front Neurol"},{"issue":"1","key":"1994_CR46","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1186\/s13287-021-02513-4","volume":"12","author":"M Amanat","year":"2021","unstructured":"Amanat M, Majmaa A, Zarrabi M, Nouri M, Akbari MG, Moaiedi AR, et al. Clinical and imaging outcomes after intrathecal injection of umbilical cord tissue mesenchymal stem cells in cerebral palsy: a randomized double-blind sham-controlled clinical trial. Stem Cell Res Ther. 2021;12(1):439. https:\/\/doi.org\/10.1186\/s13287-021-02513-4. Epub 20210806.","journal-title":"Stem Cell Res Ther"},{"issue":"6","key":"1994_CR47","doi-asserted-by":"publisher","first-page":"829","DOI":"10.2174\/1574888X17666220817125324","volume":"18","author":"A Barmada","year":"2023","unstructured":"Barmada A, Sharan J, Band N, Prodromos C. Serious Adverse Events Have Not Been Reported with Spinal Intrathecal Injection of Mesenchymal Stem Cells: A Systematic Review. Curr Stem Cell Res Ther. 2023;18(6):829\u201333. https:\/\/doi.org\/10.2174\/1574888X17666220817125324. PubMed PMID: 35980065.","journal-title":"Curr Stem Cell Res Ther"},{"issue":"2","key":"1994_CR48","doi-asserted-by":"publisher","first-page":"e1000029","DOI":"10.1371\/journal.pmed.1000029","volume":"6","author":"N Amariglio","year":"2009","unstructured":"Amariglio N, Hirshberg A, Scheithauer BW, Cohen Y, Loewenthal R, Trakhtenbrot L, et al. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med. 2009;6(2):e1000029. https:\/\/doi.org\/10.1371\/journal.pmed.1000029. PubMed PMID: 19226183; PubMed Central PMCID: PMC2642879.","journal-title":"PLoS Med"},{"key":"1994_CR49","doi-asserted-by":"publisher","first-page":"1005926","DOI":"10.3389\/fcell.2022.1005926","volume":"10","author":"K Thanaskody","year":"2022","unstructured":"Thanaskody K, Jusop AS, Tye GJ, Wan Kamarul Zaman WS, Dass SA, Nordin F. MSCs vs. iPSCs: Potential in therapeutic applications. Front Cell Dev Biol. 2022;10:1005926. https:\/\/doi.org\/10.3389\/fcell.2022.1005926. Epub 20221102.","journal-title":"Front Cell Dev Biol"},{"issue":"8","key":"1994_CR50","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1002\/mds.23770","volume":"26","author":"J Kimmelman","year":"2011","unstructured":"Kimmelman J, Duckworth K, Ramsay T, Voss T, Ravina B, Emborg ME. Risk of surgical delivery to deep nuclei: a meta-analysis. Mov Disord. 2011;26(8):1415\u201321. Epub 20110514. doi: 10.1002\/mds.23770. PubMed PMID: 21574186; PubMed Central PMCID: PMC4532377.","journal-title":"Mov Disord"},{"issue":"1","key":"1994_CR51","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/mds.29252","volume":"38","author":"R Maas","year":"2023","unstructured":"Maas R, van de Warrenburg BPC. Therapeutic Misestimation in Patients with Degenerative Ataxia: Lessons from a Randomized Controlled Trial. Mov Disord. 2023;38(1):133\u20137. Epub 20221019. doi: 10.1002\/mds.29252. PubMed PMID: 36259428; PubMed Central PMCID: PMC10092424.","journal-title":"Mov Disord"},{"issue":"Pt 11","key":"1994_CR52","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1093\/brain\/awn116","volume":"131","author":"BS Oken","year":"2008","unstructured":"Oken BS. Placebo effects: clinical aspects and neurobiology. Brain. 2008;131(Pt 11):2812\u201323. https:\/\/doi.org\/10.1093\/brain\/awn116. Epub 20080621.","journal-title":"Brain"},{"issue":"11","key":"1994_CR53","doi-asserted-by":"publisher","first-page":"e0164202","DOI":"10.1371\/journal.pone.0164202","volume":"11","author":"F Huda","year":"2016","unstructured":"Huda F, Fan Y, Suzuki M, Konno A, Matsuzaki Y, Takahashi N, et al. Fusion of Human Fetal Mesenchymal Stem Cells with Degenerating Cerebellar Neurons in Spinocerebellar Ataxia Type 1 Model Mice. PLoS ONE. 2016;11(11):e0164202. https:\/\/doi.org\/10.1371\/journal.pone.0164202. Epub 20161101.","journal-title":"PLoS ONE"},{"key":"1994_CR54","doi-asserted-by":"publisher","first-page":"569293","DOI":"10.3389\/fmolb.2020.569293","volume":"7","author":"FM Smith","year":"2020","unstructured":"Smith FM, Kosman DJ. Molecular Defects in Friedreich\u2019s Ataxia: Convergence of Oxidative Stress and Cytoskeletal Abnormalities. Front Mol Biosci. 2020;7:569293. Epub 20201109. doi: 10.3389\/fmolb.2020.569293. PubMed PMID: 33263002; PubMed Central PMCID: PMC7686857.","journal-title":"Front Mol Biosci"},{"issue":"5","key":"1994_CR55","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s12311-025-01899-8","volume":"24","author":"K Bando","year":"2025","unstructured":"Bando K, Kondo Y, Ariake Y, Kato T, Oba MS, Hara T, et al. Long-Term Effects of Annual Intensive Rehabilitation in Patients with Hereditary Pure Cerebellar Ataxia: A 7-year Follow-up Study. Cerebellum. 2025;24(5):150. https:\/\/doi.org\/10.1007\/s12311-025-01899-8. Epub 20250904.","journal-title":"Cerebellum"},{"issue":"1","key":"1994_CR56","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/ana.23612","volume":"72","author":"PH Lee","year":"2012","unstructured":"Lee PH, Lee JE, Kim HS, Song SK, Lee HS, Nam HS, et al. A randomized trial of mesenchymal stem cells in multiple system atrophy. Ann Neurol. 2012;72(1):32\u201340. .23612. PubMed PMID: 22829267.","journal-title":"Ann Neurol"},{"issue":"1","key":"1994_CR57","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.1212\/WNL.0000000000007720","volume":"93","author":"W Singer","year":"2019","unstructured":"Singer W, Dietz AB, Zeller AD, Gehrking TL, Schmelzer JD, Schmeichel AM, et al. Intrathecal administration of autologous mesenchymal stem cells in multiple system atrophy. Neurology. 2019;93(1):e77\u201387. Epub 20190531. doi: 10.1212\/WNL.0000000000007720. PubMed PMID: 31152011; PubMed Central PMCID: PMC6659003.","journal-title":"Neurology"},{"key":"1994_CR58","unstructured":"Lasserson TJ, Thomas J, Higgins JPT. Chapter 1: Starting a review [last updated August 2021]. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.5. Cochrane; 2024. p. 10. Available from: https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current\/chapter-01"},{"issue":"6","key":"1994_CR59","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/s41583-023-00697-7","volume":"24","author":"N Stefanova","year":"2023","unstructured":"Stefanova N, Wenning GK. Multiple system atrophy: at the crossroads of cellular, molecular and genetic mechanisms. Nat Rev Neurosci. 2023;24(6):334\u201346. https:\/\/doi.org\/10.1038\/s41583-023-00697-7. Epub 20230421.","journal-title":"Nat Rev Neurosci"},{"key":"1994_CR60","unstructured":"Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy [MeSH Descriptor]. National Library of Medicine (US). 2021. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05167721"},{"issue":"3","key":"1994_CR61","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s12311-022-01403-6","volume":"22","author":"M Bhartiya","year":"2023","unstructured":"Bhartiya M, Kumar A, Singh RK, Radhakrishnan DM, Rajan R, Srivastava AK. Mesenchymal Stem Cell Therapy in the Treatment of Neurodegenerative Cerebellar Ataxias: a Systematic Review and Meta-analysis. Cerebellum. 2023;22(3):363\u20139. https:\/\/doi.org\/10.1007\/s12311-022-01403-6. Epub 20220422.","journal-title":"Cerebellum"},{"issue":"1","key":"1994_CR62","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40673-021-00130-8","volume":"8","author":"PA Appelt","year":"2021","unstructured":"Appelt PA, Comella K, de Souza L, Luvizutto GJ. Effect of stem cell treatment on functional recovery of spinocerebellar ataxia: systematic review and meta-analysis. Cerebellum Ataxias. 2021;8(1):8. https:\/\/doi.org\/10.1186\/s40673-021-00130-8. Epub 20210225.","journal-title":"Cerebellum Ataxias"},{"issue":"1","key":"1994_CR63","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2174\/1570159X16666180917105033","volume":"17","author":"H Mitoma","year":"2019","unstructured":"Mitoma H, Manto M, Hampe CS. Immune-mediated Cerebellar Ataxias: Practical Guidelines and Therapeutic Challenges. Curr Neuropharmacol. 2019;17(1):33\u201358. doi: 10.2174\/1570159X16666180917105033. PubMed PMID: 30221603; PubMed Central PMCID: PMC6341499.","journal-title":"Curr Neuropharmacol"},{"issue":"8","key":"1994_CR64","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.3201\/eid2908.230317","volume":"29","author":"AB Wolf","year":"2023","unstructured":"Wolf AB, Money KM, Chandnani A, Daley CL, Griffith DE, Chauhan L, et al. Mycobacterium abscessus Meningitis Associated with Stem Cell Treatment During Medical Tourism. Emerg Infect Dis. 2023;29(8):1655\u20138. https:\/\/doi.org\/10.3201\/eid2908.230317. PubMed PMID: 37486227; PubMed Central PMCID: PMC10370854.","journal-title":"Emerg Infect Dis"},{"issue":"3","key":"1994_CR65","doi-asserted-by":"publisher","first-page":"e0119632","DOI":"10.1371\/journal.pone.0119632","volume":"10","author":"H Liu-Seifert","year":"2015","unstructured":"Liu-Seifert H, Andersen SW, Lipkovich I, Holdridge KC, Siemers E. A novel approach to delayed-start analyses for demonstrating disease-modifying effects in Alzheimer\u2019s disease. PLoS ONE. 2015;10(3):e0119632. https:\/\/doi.org\/10.1371\/journal.pone.0119632. Epub 20150317.","journal-title":"PLoS ONE"},{"issue":"8","key":"1994_CR66","doi-asserted-by":"publisher","first-page":"e209876","DOI":"10.1212\/WNL.0000000000209876","volume":"103","author":"KS Hayward","year":"2024","unstructured":"Hayward KS, Dalton EJ, Campbell BCV, Khatri P, Dukelow SP, Johns H, et al. Adaptive Trials in Stroke: Current Use and Future Directions. Neurology. 2024;103(8):e209876. Epub 20240926. doi: 10.1212\/WNL.0000000000209876. PubMed PMID: 39325999; PubMed Central PMCID: PMC11436319.","journal-title":"Neurology"},{"key":"1994_CR67","doi-asserted-by":"publisher","unstructured":"Ursino M, Stallard N. Bayesian Approaches for Confirmatory Trials in Rare Diseases: Opportunities and Challenges. Int J Environ Res Public Health. 2021;18(3). Epub 20210124. https:\/\/doi.org\/10.3390\/ijerph18031022. PubMed PMID: 33498915; PubMed Central PMCID: PMC7908592.","DOI":"10.3390\/ijerph18031022"},{"issue":"1","key":"1994_CR68","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s13023-022-02342-5","volume":"17","author":"KM Kidwell","year":"2022","unstructured":"Kidwell KM, Roychoudhury S, Wendelberger B, Scott J, Moroz T, Yin S, et al. Application of Bayesian methods to accelerate rare disease drug development: scopes and hurdles. Orphanet J Rare Dis. 2022;17(1):186. https:\/\/doi.org\/10.1186\/s13023-022-02342-5. Epub 20220507.","journal-title":"Orphanet J Rare Dis"}],"container-title":["The Cerebellum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12311-026-01994-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12311-026-01994-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12311-026-01994-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T04:26:48Z","timestamp":1780460808000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12311-026-01994-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":68,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["1994"],"URL":"https:\/\/doi.org\/10.1007\/s12311-026-01994-4","relation":{"references":[{"id-type":"doi","id":"10.1136\/bmj.n71","asserted-by":"subject"},{"id-type":"doi","id":"10.3389\/fimmu.2018.02000","asserted-by":"subject"}]},"ISSN":["1473-4230"],"issn-type":[{"value":"1473-4230","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"25 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This manuscript does not contain any individual person\u2019s data in any form.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethics approval is not applicable since this article is a systematic review of previously published studies and involved no new research with human participants or animals conducted by the authors. The review was conducted in accordance with the ethical principles of the Declaration of Helsinki and complied with PRISMA 2020 reporting guideline. The completed PRISMA 2020 checklist is provided as Supplementary File\n                      \n                      . Institutional review board approval and informed consent were not required for this study type. Consent to participate is not applicable as no new human participants were enrolled by the authors; all data were extracted from publicly available reports that obtained ethics approval and consent in their original studies.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human Ethics and Consent to Participate"}},{"value":"not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical Trial Number"}},{"value":"An AI-assisted tool (ChatGPT; OpenAI, San Francisco, CA) was used to aid translation of non-English articles during screening. The authors manually checked all translations and take full responsibility for the content. No AI tool was used to generate original scientific content, analysis, or conclusions.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Use of generative AI"}}],"article-number":"52"}}